Tag: Food and Drug Administration

FDA Seeking Public Input on Cannabis Reclassification

The Food and Drug Administration (FDA) is again soliciting public feedback on the potential cannabis reclassification under international treaties. The agency announced in a draft Federal Register notice released on Wednesday that it is reopening a comment period for 30 days, giving people another opportunity to shape the U.S. response to an ongoing United Nations […]

Read More…

Here Is How the FDA is Handling the Mainstream CBD Boom

You may have noticed that cannabidiol (CBD) seems to be available almost everywhere, and marketed as a variety of products including drugs, food, dietary supplements, cosmetics, pet food, and other animal health products. The U.S. Food and Drug Administration (FDA) recognizes the significant mainstream CBD boom and the public interest in cannabis and cannabis-derived compounds, […]

Read More…

CBD-Based Pharma Drug Submitted To FDA For Approval

Will the FDA approve its first CBD-based drug? Epidiolex, a pharmaceutical made by UK-based company GW Pharmaceuticals plc (known as Greenwich Biosciences in the US), is a CBD-based drug that’s targeted specifically to patients who suffer seizures due to either Dravets syndrome or Lennox-Gastaut syndrome. The New Drug Application for Epidiolex was just submitted to the […]

Read More…

FDA Goes After CBD Companies

“Substances that contain components of marijuana will be treated like any other products that make unproven claims to shrink cancer tumors.” said FDA Commissioner Scott Gottleib in a statement to CBD companies. “We don’t let companies market products that deliberately prey on sick people with baseless claims that their substance can shrink or cure cancer and […]

Read More…

FDA Might Go After Marijuana Products That Claim Health Benefits

Some interesting developments were had in a hearing before the Senate Committee on Health, Education, Labor and Pensions, where Scott Gottleib, President Trump’s pick to lead the FDA, answered questions about his stances and the direction the FDA would go in under his care. In that conversation, Gottleib assured lawmakers that his previous private sector connections would […]

Read More…